Treatment For Gram-Negative Bacteria Ultimate Target Of N-Rephasin® Technology
Bacteria can be identified by Gram-staining and are divided into two groups- Gram negative and Gram positive. Particularly, Gram negative bacteria cause many serious infection problems, but there hasn’t been a powerful solution against them. Among all Gram negative bacteria, Salmonella, Acinetobacter baumannii, Escherichia coli, Pseudomonas aeruginosa, and Klebsiella pneumoniae are the most problematic.
Our BACASEs targets Gram negative bacteria and are based on N-Rephasin Technology. There are 5 different promising candidates.
We have been investigating these candidates and improving their efficacy against the most problematic Gram negative bacteria through a series of treatment experiments. Starting from this point, we have plans to conduct clinical investigations through various efficacy-related experiments. If we succeed in developing these candidates as new antibacterials, we expect our Gram negative BACASEs to become an important next generation technology to solve the urgent infectious problems in human healthcare.
TonaBACASE (SAL200), An Anti-MRSA Drug
Pipeline Of N-Rephasin® Technology At The Forefront
We have TonaBACASE (SAL200), a novel drug candidate targeting the worsening problem of MRSA (VRSA) among Gram positive bacterial infections.
Conventional antibiotics are continuously having serious resistance problems and this accentuates the necessity to develop new types of antibiotics. However, current small molecule antibiotics seem to have reached their development potential limits. In this context, we believe that Endolysin (a novel type antibacterial)-based on the N-Rephasin Technology- will be soon highlighted as solid alternative to current antibiotics.
TonaBACASE is a novel drug candidate based on Endolysin and it successfully completed a Phase I clinical trial in humans. This clinical trial constitutes the first-in-human phase 1 study of an intravenously administered, phage endolysin-based drug. This clinical trial proved that Endolysin-based TonaBACASE is safe for human applications.
Our next step on the basis of the safety results of Endolysin-based TonaBACASE in a human, we initiated a Phase II clinical trial in patients with MRSA/MSSA infections.
‘Endolysin’ Is The Ultimate Solution
To Bacterial Resistance Problem
Endolysin is a ‘Bactericidal Enzyme’ and bacteria-killing antibiotic whose mode of action is to destroy the bacterial cell wall. Most conventional synthetic antibiotics work by inhibiting bacterial proliferation and are classified as bacteriostatic antibiotics. They also induce the development of resistance in bacteria to synthetic antibiotics.
Endolysin has the ability to cleavage specific linkages in the bacterial peptidoglycan layer as its mode of action. This characteristic offers Endolysin the power to solve a fundamental problem of resistance, and that is why Endolysin is a totally new type of antibiotic, functioning completely different from that of conventional antibiotics.
Endolysin has many sub-types and it is an enzyme derived from Bacteriophage, a parasite of bacteria, used to destroy the host. Based on ‘Endolysin Platform Technology’ which is a combined protein engineering and genetic recombination, we have developed endolysin based new drug. Endolysin contains powerful bactericidal capabilities.
Platform Technology For the Development And Improvement Of Endolysin
We have established N-Rephasin Technology, a platform technology for the development and improvement of Endolysin. N-Rephasin Technology comprises of Bacteriophage technologies (ex. bacteriophage screening technology, bacteriophage enrichment technology, bacteriophage genome analysis technology, etc.) and Endolysin technologies (ex. function-structure modulation technology, formulation technology, truncation technology, etc.).
The official substance pre-stem given and registered with the WHO for Endolysins developed through ‘N-Rephasin Technology’ is ‘-bacase’, which confers the meaning of a novel bactericidal enzyme.
SAL200, iNtRON’s new anti-MRSA drug candidate, has an officially registered name assigned by the WHO- “Tonabacase”. Tona means Tornado (a type of hurricane) and Bacase means bactericidal enzyme. Experts appraised that the name Tonabacase suits SAL200 well because SAL200 has a powerful bacteria-killing ability, and it will be readily recognized by physicians in the future as a superior bacterial infection treatment medication.